Back

Comorbidity burden in transthyretin amyloidosis with cardiomyopathy: insights from the HELIOS-B trial

12 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Risk factors and comorbidities Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Sarah Birkhoelzer

University Dorset Hospital, Bournemouth (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Refining iron deficiency definitions in acute hospitalised heart failure
Doctor H. Oh (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Recovery of worsening renal function after acute heart failure
Doctor D. Cocianni (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Anemia subtypes increase the risk of peripartum cardiomyopathy and time to presentation independently of maternal race
Miss K. Sompel (Aurora, US)
Abstract Slides Video
Presentation thumbnail
Blood transfusion-associated sepsis during cardiogenic shock: a subanalysis from the SHARK-SHOCK registry
Doctor N. Ghionzoli (Harefield, GB)
Abstract Slides Video
Presentation thumbnail
Frailty does not always matter: insights from an elderly, multimorbid acute heart failure cohort (RICA-2 registry)
Doctor D. Chivite Guillen (Hospitalet De Llobregat, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and comorbidities

The Event

Event poster

Heart Failure 2026

12 May 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Effect of vutrisiran in patients with and without atrial fibrillation or flutter: analysis from HELIOS-B
thumbnail
Congress Presentation
HELIOS-B: Vutrisiran reduces all-cause mortality

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources